Shaky Danny

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine has come out in the New England Journal of Medicine. I was wrong again. I thought the 95% was a consequence of confusion between oncology and epidemiology. The study was conducted by Pfizer. I had thought it was fortuitous that an mRNA vaccine that avoids the issue of white blood cell response was easier to develop. The study:  “ RESULTS A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among...

  Foreign cells have the ability to resist our immune system. When Sars-Cov2 infects a foreign cell, it will be coated in that cell’s glycan. Depending on the cell that is infected the new virus will either awaken our immune response or avoid it. In those cases where the glycan is part of the foreign cells immune defense, the new virus will also have that capability. This speculation is to explain why some people are more infectious. When Sars-Cov2 infects strep for instance, those virus particles may be transmitted more easily.